Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight

Advertisement

The increasing prevalence of autoimmune disorders, including conditions like Rheumatoid Arthritis, Type I Diabetes, and Addison’s Disease, is a key driver for the growing demand for autoimmune disease diagnostics. Furthermore, heightened public awareness of the importance of early disease detection and continuous technological advancements in the healthcare sector are significant factors fueling the expansion of the autoimmune diseases diagnostics market throughout the forecast period from 2023–2028.

New York, USA, Dec. 21, 2023 (GLOBE NEWSWIRE) — Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight

The increasing prevalence of autoimmune disorders, including conditions like Rheumatoid Arthritis, Type I Diabetes, and Addison’s Disease, is a key driver for the growing demand for autoimmune disease diagnostics. Furthermore, heightened public awareness of the importance of early disease detection and continuous technological advancements in the healthcare sector are significant factors fueling the expansion of the autoimmune diseases diagnostics market throughout the forecast period from 2023–2028.

Advertisement

DelveInsight’s Autoimmune Diseases Diagnostics Market Insights report provides the current and forecast market analysis, individual leading autoimmune diseases diagnostics companies’ market shares, challenges, autoimmune diseases diagnostics market drivers, barriers, trends, and key market autoimmune diseases diagnostics companies in the market.

Key Takeaways from the Autoimmune Diseases Diagnostics Market Report

  • As per DelveInsight estimates, North America is anticipated to dominate the global autoimmune diseases diagnostics market during the forecast period. 
  • Notable autoimmune diseases diagnostics companies such as Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, Werfen, Bio-Rad Laboratories, Exagen Inc., Grifols, S.A, Medical & Biological Laboratories Co. Ltd, RSR Limited, DiaSorin S.p.A, Laboratory Corporation of America Holdings, Abcam plc, EUROIMMUN Medizinische Labordiagnostika AG, Quest Diagnostics, Hemagen Diagnostics, Inc., AESKU Diagnostics GmbH & Co. KG, Trinity Biotech and Biomerieux SA., and several others, are currently operating in the autoimmune diseases diagnostics market.
  • In October 2022, Sebia, a global specialty diagnostic company engaged in providing innovative solutions for screening and diagnosis of oncological, metabolic, genetic, and autoimmune disorders, acquired ZEUS Scientific.
  • In May 2022, Thermofisher Scientific launched The new Phadia 2500+ series in the US, for the diagnosis of autoimmune disorders.

To read more about the latest highlights related to the autoimmune diseases diagnostics market, get a snapshot of the key highlights entailed in the Global Autoimmune Diseases Diagnostics Market Report

Autoimmune Diseases Diagnostics Overview

Autoimmune disease diagnostics play a crucial role in identifying and managing conditions where the immune system mistakenly attacks the body’s own cells. Advanced diagnostic technologies have revolutionized the detection of autoimmune diseases, enabling early and accurate identification of these complex disorders. Laboratory tests such as autoantibody assays, cytokine profiling, and genetic testing contribute to the comprehensive evaluation of autoimmune conditions. Cutting-edge techniques, including next-generation sequencing and multiplex assays, enhance the precision and efficiency of autoimmune disease diagnostics. These methods enable healthcare professionals to differentiate between various autoimmune disorders, facilitating targeted treatment plans. Rapid advancements in the field continue to improve diagnostic accuracy, ultimately leading to better outcomes for individuals affected by autoimmune diseases. Early detection through sophisticated diagnostic tools empowers healthcare providers to initiate timely interventions, thereby improving the quality of life for patients with autoimmune conditions.

Autoimmune Diseases Diagnostics Market Insights 

North America is anticipated to hold the predominant share in the autoimmune disease diagnostics market in the coming years among all global regions. This leadership position is attributed to the substantial presence of patients grappling with autoimmune disorders in the region. Moreover, heightened public awareness regarding disease diagnosis, governmental backing, and a robust market environment for product innovation and introductions collectively contribute to propelling the growth trajectory of the autoimmune disease diagnostics market in North America.

To know more about why North America is leading the market growth in the autoimmune diseases diagnostics market, get a snapshot of the Autoimmune Diseases Diagnostics Market Outlook 

Autoimmune Diseases Diagnostics Market Dynamics

The escalating incidence of autoimmune disorders is anticipated to drive the demand for autoimmune disease diagnostics, fostering positive growth in the autoimmune disease diagnostics market. Additionally, the heightened awareness among individuals regarding the importance of early disease detection and continuous technological advancements in healthcare further contribute to the upward trajectory of the autoimmune disease diagnostics Market during the forecast period from 2023–2028.

Furthermore, the increasing prevalence of autoimmune disorders necessitates timely diagnosis, propelling the autoimmune disease diagnostic Market forward. An additional catalyst for autoimmune disease diagnostic market growth is the expanding public awareness campaigns, such as Autoimmune Disease Awareness Month in March, organized by the Autoimmune Association. These initiatives aim to enhance public understanding of autoimmune diseases, thereby stimulating the demand for early disease detection and positively impacting the autoimmune disease diagnostics market.

Nevertheless, challenges such as the high cost associated with autoimmune disease diagnosis, prolonged turnaround times, and the necessity for multiple tests remain noteworthy constraints that could impede the overall growth of the autoimmune disease diagnostic market.

Get a sneak peek at the autoimmune diseases diagnostics market dynamics @ Autoimmune Diseases Diagnostics Market Dynamics Analysis

Report Metrics Details
Coverage Global
Study Period 2020–2028
Autoimmune Diseases Diagnostics Market CAGR ~6%
Autoimmune Diseases Diagnostics Market Size by 2028 USD 6.41 Billion
Key Autoimmune Diseases Diagnostics Companies Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, Werfen, Bio-Rad Laboratories, Exagen Inc., Grifols, S.A, Medical & Biological Laboratories Co. Ltd, RSR Limited, DiaSorin S.p.A, Laboratory Corporation of America Holdings, Abcam plc, EUROIMMUN Medizinische Labordiagnostika AG, Quest Diagnostics, Hemagen Diagnostics, Inc., AESKU Diagnostics GmbH & Co. KG, Trinity Biotech and Biomerieux SA., among others

Autoimmune Diseases Diagnostics Market Assessment

  • Autoimmune Diseases Diagnostics Market Segmentation
    • Autoimmune Diseases Diagnostics Market Segmentation By Product: Reagents & Kits and Instruments
    • Autoimmune Diseases Diagnostics Market Segmentation By Disease Type: Localized Autoimmune Disease, and Systemic Autoimmune Disease
    • Autoimmune Diseases Diagnostics Market Segmentation By Test: Antinuclear Antibody Test, Autoantibody Test, Complete Blood Count, Comprehensive Metabolic Panel, C-Reaction Protein, Erythrocyte Sedimentation Rate, and Urinalysis
    • Autoimmune Diseases Diagnostics Market Segmentation By End User: Hospitals & Clinics, Diagnostics Centers, and Others
    • Autoimmune Diseases Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the autoimmune diseases diagnostics market are set to emerge as the trendsetter explore @ Autoimmune Diseases Diagnostics Companies 

Table of Contents 

1 Report Introduction
2 Executive summary
3 Regulatory and Patent Analysis
4 Key Factors Analysis
5 Porter’s Five Forces Analysis
6 COVID-19 Impact Analysis on Autoimmune Diseases Diagnostics Market
7 Autoimmune Diseases Diagnostics Market Layout
8 Global Company Share Analysis – Key 3-5 Companies
9 Autoimmune Diseases Diagnostics Market Company and Product Profiles
10 Project Approach
11 About DelveInsight

Interested in knowing the autoimmune diseases diagnostics market by 2028? Click to get a snapshot of the Autoimmune Diseases Diagnostics Market Trends

Related Reports

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, among others.

Rheumatoid Arthritis Pipeline

Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key rheumatoid arthritis companies, including Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, among others.

Juvenile Rheumatoid Arthritis Pipeline

Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, GeneScience Pharmaceuticals, Cerecor, Bio-Thera solutions, Mycenax Biotech, Boehringer Ingelheim, among others.

Juvenile Rheumatoid Arthritis Market

Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, GeneScience Pharmaceuticals, Cerecor, Bio-Thera solutions, Mycenax Biotech, Boehringer Ingelheim, among others.

Psoriatic Arthritis Pipeline

Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, among others.

Psoriatic Arthritis Market

Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cadilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

CONTACT: Contact Us Shruti Thakur  [email protected]  +91-9650213330  https://www.delveinsight.com/medical-devices

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.